Trends in Use of Second-Generation Antipsychotics for Treatment of Bipolar Disorder in the United States, 1998–2009
Open accessAbstract
OBJECTIVE: The authors examined trends in the use of second-generation antipsychotics for treatment of bipolar disorder before and after the U.S. Food and Drug Administration's approval in 2000 of olanzapine for use in treating acute manic episodes of bipolar disorder. METHODS: The IMS Health National Disease and Therapeutic Index was used to derive monthly patient treatment visits between January 1998 and December 2009 by individuals 18 and older with a diagnosis of bipolar disorder who were treated with one or more pharmacotherapies. RESULTS: The percentage of treatment visits in which a second-generation antipsychotic was prescribed increased from 18% in 1998 to 49% in 2009. Use of mood stabilizers and first-generation antipsychotics declined substantially. In the 12 months after approval of olanzapine for bipolar disorder, its use increased by 92%, and use of other second-generation antipsychotics increased by 42%. CONCLUSIONS: Second-generation antipsychotics are increasingly used for bipolar disorder, and their effectiveness compared with therapeutic alternatives merits further research.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antipsychotic medications are increasingly used as first line treatments for bipolar disorder and MDD.
“Since antipsychotic medications are increasingly used as first line treatments for bipolar disorder 43 and MDD 44”
From Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis (2016) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Physicians and the Pharmaceutical Industry
Wazana, A. D. (2000) · JAMA · doi:10.1001/jama.283.3.373 · Cited by 1,418 · see citing works
Jones, P., Barnes, T., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R., Markwick, A., & Lewis, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,060 · see citing works
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · see citing works
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., AMBLER, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 476 · see citing works
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Alexander, G. C., Gallagher, S. A., Mascola, A. J., Moloney, R., & Stafford, R. S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2082 · Cited by 421 · see citing works
Self-citationThe underutilization of cardiacmedications of proven benefit, 1990 to 2002
Stafford, R. S., & Radley, D. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02670-0 · Cited by 286 · see citing works
Impact of FDA Black Box Advisory on Antipsychotic Medication Use
Dorsey, E. R. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.456 · Cited by 240 · see citing works
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
van Winkel, R., Binder, M. D., Eyck, D. V., Hanssens, L., Wampers, M., Scheen, A. J., & Peuskens, J. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00520.x · Cited by 187 · see citing works
Generalized Estimating Equations
(2004) · The SAGE Encyclopedia of Social Science Research Methods · doi:10.4135/9781412950589.n369 · Cited by 171 · see citing works
Are drugs within a class interchangeable?
Furberg, C. D., Herrington, D. M., & Psaty, B. M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03190-6 · Cited by 120 · see citing works
Rosenheck, R. A., LESLIE, D. L., & Doshi, J. A. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.5.515 · Cited by 38 · see citing works
National Trends in Ambulatory Asthma Treatment, 1997–2009
Higashi, A. S., Zhu, S., Stafford, R. S., & Alexander, G. C. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1796-4 · Cited by 37 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [6]Berndt ER Bui L Reiley D The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the US Anti-Ulcer Drug Industry NBER working paper 4904 1994 Cambridge, Mass National Bureau of Economic Research Available at www.nber.org/papers
Cited by
Sorted by citations
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729 · see citing works
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271 · see citing works
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659 · see citing works
Lee, K., Abraham, S., & Cleaver, R. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.07.006 · Cited by 53 · see citing works
Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis
Szmulewicz, A. G., Angriman, F., Samamé, C., Ferraris, A., Vigo, D., & Strejilevich, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12712 · Cited by 37 · see citing works
Szmulewicz, A., Samamé, C., Caravotta, P., Martino, D. J., Igoa, A., Hidalgo-Mazzei, D., Colom, F., & Strejilevich, S. A. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0047-3 · Cited by 28 · see citing works
- Authors
- Pillarella, J., Higashi, A., Alexander, G. C., & Conti, R.
- Affiliations
- University of Chicago (US)
- Venue
- Psychiatric Services
- Published
- 2012-01
- Volume
- 63
- Issue
- 1
- Pages
- 83-86
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- PMC
- PMC4594841
- OpenAlex
- W2112093688
- Cited by
- 53
- References
- 12
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 7 · 2014: 5 · 2013: 3 · 2012: 4
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Agency for Healthcare Research and Quality (RO1 HS0189960, R01-HS-0189960)
- National Institute on Aging (T35AG029795)
- National Cancer Institute (K07CA138906)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- bipolar disorder, atypical antipsychotics, olanzapine, prescribing trends, FDA drug approval, mood stabilizers, typical antipsychotics, acute mania
- MeSH terms
- Olanzapine, Antidepressive Agents, Benzodiazepines, Bipolar Disorder, Drug Therapy, Combination, Drug Utilization, Humans, Practice Patterns, Physicians', Antipsychotic Agents, United States, United States Food and Drug Administration, Models, Statistical, Drug Approval, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
